Otsuka America launches new unit focused on digital therapeutics, AI and mental health

By SharpBrains | June 10, 2024 |

Otsu­ka defies dig­i­tal health down­turn with new com­pa­ny (MedTech­Dive): Otsu­ka Amer­i­ca, a sub­sidiary of the Japan­ese drug and device mak­er, this month launched a new com­pa­ny focused on dig­i­tal health. The firm, called Otsu­ka Pre­ci­sion Health, will roll out its first prod­uct this sum­mer, a pre­scrip­tion dig­i­tal ther­a­peu­tic for major depres­sive dis­or­der. San­ket Shah, who…

Read More

Could I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning

By SharpBrains | November 30, 2021

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eight time­ly sci­en­tif­ic and indus­try news plus a few fun teasers to appre­ci­ate our unique human brains. #1. Could I be wrong? Explor­ing research on cog­ni­tive bias, curios­i­ty, intel­lec­tu­al humil­i­ty, and life­long learn­ing “None of us thinks that our beliefs and atti­tudes are incor­rect; if we…

Read More

Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more

By SharpBrains | November 4, 2021

With Sanofi still on board, Click Ther­a­peu­tics clos­es $52M series B for dig­i­tal ther­a­peu­tics in depres­sion, chron­ic pain and more (Fierce Biotech): Anoth­er medtech devel­op­er’s plans to cre­ate dig­i­tal ther­a­peu­tics to treat a wide range of ill­ness­es are click­ing into place, thanks to a third mul­ti­mil­lion-dol­lar invest­ment in Click Ther­a­peu­tics in bare­ly a year.

Read More

Innovation in COVID times: Otsuka and Click Therapeutics announce fully virtual clinical trial, leveraging Verily’s Project Baseline

By SharpBrains | March 19, 2021

Otsu­ka launch­es piv­otal tri­al of dig­i­tal ther­a­peu­tics for depres­sion (Med­C­i­ty News): Otsu­ka Phar­ma­ceu­ti­cal is launch­ing a vir­tu­al study to see if dig­i­tal ther­a­peu­tics can reduce depres­sion symp­toms. It’s the next step in a part­ner­ship between the Tokyo-based drug­mak­er and Click Ther­a­peu­tics, a dig­i­tal health start­up that is devel­op­ing pro­grams for smok­ing ces­sa­tion, depres­sion and insomnia.

Read More

Update: Understanding Brain Health via Cosmological Health, and vice versa

By SharpBrains | December 29, 2020

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing fas­ci­nat­ing find­ings, books and resources for life­long brain health. #1. “The human brain (sec­tion; left image above) func­tions thanks to its wide neu­ronal net­work that is deemed to con­tain approx­i­mate­ly 69 bil­lion neu­rons. On the oth­er hand, the observ­able uni­verse (sec­tion sim­u­la­tion; right image) can count…

Read More

Click Therapeutics raises $30 million in debt to advance commercialization of smoking cessation app Clickotine

By SharpBrains | December 4, 2020

Click Ther­a­peu­tics Secures $30M in Growth Cap­i­tal from K2 HealthVen­tures to Expand Oper­a­tions (press release): Click Ther­a­peu­tics, Inc. (“Click”), a leader in Dig­i­tal Ther­a­peu­tics™ solu­tions as pre­scrip­tion med­ical treat­ments, today announced $30 mil­lion in debt financ­ing from K2 HealthVen­tures (K2HV), a health­­care-focused spe­cial­ty finance com­pa­ny, to accel­er­ate com­mer­cial­iza­tion of its lead­ing smok­ing ces­sa­tion solu­tion, Clickotine™,…

Read More